







781, Industrial Area, Phase II, Chandigarh-160 002 INDIA

Ph. 0172-4680800, 2638781 Fax. 0172-2652242

E-mail: corporate@indswift.com CIN NO: L24230CH1986PLC006897

Ref.: ISL:CH:2020:

The President,
Corporate Relationship Department,
Bombay Stock Exchange Limited,
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai 400 001

Date: 27th March, 2020

The Vice President
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No. C/2, G-Block,
Bandra Kurla Complex, Bandra (E)
Mumbai 400 051

BSE Scrip Code: 524652

NSE Symbol: INDSWFTLTD

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that as the threat from the COVID-19 pandemic continues to accelerate, the Company is taking appropriate measures to ensure the safety and well-being of all its employees and ensuring full compliance with the directives issued by Central & State Governments as well as local administration in this regard.

The Company has already adopted "Work from Home" for all its office-based employees from 23rd March, 2020 to minimize the spread of COVID-19. For the safety of people employed in on-ground operations, we have put in place various measures on social distancing and precautionary hygienic practices.

The Indian government has announced a nationwide lockdown for 21 days from the 25th of March 2020, to stem the proliferation of COVID-19. Due to this, the operations in our Manufacturing Units, and Research & Development Center have been disrupted. We have had to scale down the operations in most of our operating locations.

Ind-Swift Limited is fully supportive of the Indian government's decision and is aligned with the authorities to address this national emergency. We had already created a task force to deal with this pandemic situation. Since we are involved in manufacturing of essential drugs, we are assessing the impact of the lockdown on our ability to continue with manufacturing operations of essential products, in order to meet our commitments to patients, customers and partners. While supply chain disruptions and impaired mobility due to lockdowns have a direct bearing on our operations, we are working to minimize disruption to production schedules and supply of drugs to our customers and partners. We do anticipate delayed deliveries for some products due to partial shutdown and changes in production schedule and restriction of goods movement within and outside India. We are engaging with our vendors to secure supplies of various raw materials but they are also in a similar situation.













781, Industrial Area, Phase II, Chandigarh-160 002 INDIA Ph. 0172-4680800, 2638781 Fax. 0172-2652242

E-mail: corporate@indswift.com CIN NO: L24230CH1986PLC006897

We are closely monitoring the situation and will ensure compliance with all the directives of Central government, State government and local administration to contain the spread of COVID-19. The impact on the business operations is difficult to assess at this point as the situation continues to evolve at a rapid pace.

You are requested to take the above information on record.

Thanking You.

Yours Faithfully, For IND SWIFT LIMITED

AMRENDER KUMAR YADAV

COMPANY SECRETARY



